Adams Kendra sold 45,173 shares of C4 Therapeutics, Inc. at $2.71 for −$122k on Nov 12, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Financial Officer
Chief Financial Officer
Filed Nov 13, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$122,486.59Shares × reported price
Shares traded
45,173Common Stock
Price per share
$2.71Reported price. Read footnotes for ranges.
% of reported position traded
11.82%This security and ownership context
Holdings after
337,150Direct
Trade date
Nov 12, 2026Sell
Filed
Nov 13, 2026, 4:10 PM ET1-day reporting delay
Accession
0001470831-26-001003Code S · Transaction 400565
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 382,323 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

CCCC price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CCCC · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 20, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −18%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2026. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.645 to $2.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.